24 | Chapter 1 Figure 4. Shared decision making model as developed by Elwyn et al. (2017)48 Patients facing HNC treatments should therefore make preference-sensitive decisions, where the trade-offs between treatment efficacy, side effects, and impacts on quality of life are complex and deeply personal. Despite the recognized value of SDM in these cases, research on its application in head and neck oncology is scarce, highlighting a gap in understanding how best to support these patients in their treatment decisions54. As mentioned earlier, early-stage oropharyngeal cancer poses preference-sensitive choices between radiation and transoral surgery, while advanced laryngeal cancer presents treatment options with notable side effects and survival trade-offs. We therefore have chosen to investigate these conditions in the context of Patient Decision Aids (PDAs). While our research has primarily focused on the development of a PDA for early-stage oropharyngeal cancer, we have also tested the impact of an earlier developed PDA for advanced laryngeal cancer55.
RkJQdWJsaXNoZXIy MTk4NDMw